---
schema_version: "secwatch.filing_event.v1"
accession: "0001390478-26-000009"
form_type: "8-K"
ticker: "SLS"
cik: "0001390478"
company_name: "SELLAS Life Sciences Group, Inc."
filed_at: "2026-05-12T20:07:20+00:00"
generated_at: "2026-05-12T21:25:38.727432+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# SELLAS reports 78 events in REGAL AML trial; Q1 net loss $8.4M, cash $107.1M

## Summary
- 78 events (deaths) occurred in pivotal Phase 3 REGAL trial of GPS in AML as of May 11; final analysis triggered at 80th event.
- Cash and cash equivalents $107.1M at March 31, 2026; additional $7.5M from warrant exercises received in Q2 2026.
- Net loss $8.4M for Q1 2026 ($0.05 per share) vs $5.8M loss ($0.07 per share) in Q1 2025.
- Phase 2 trial of SLS009 in first-line AML dosing patients; topline data expected in Q4 2026.
- R&D expenses $5.1M (up from $3.2M); G&A $4.1M (up from $2.9M) driven by BLA preparation and professional fees.

## SEC filing metadata
- accession: 0001390478-26-000009
- form_type: 8-K
- ticker: SLS
- cik: 0001390478
- company_name: SELLAS Life Sciences Group, Inc.
- filed_at: 2026-05-12T20:07:20+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1390478/000139047826000009/0001390478-26-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1390478/000139047826000009/sls-20260512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001390478-26-000009
- JSON: https://secwatch.observer/filing/0001390478-26-000009.json
- Plain text: https://secwatch.observer/filing/0001390478-26-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.